Atorvastatin versus rosuvastatin in non-diabetic patients with dyslipidemia: a comparative study
Keywords:Atorvastatin, Rosuvastatin, Statins, Triglycerides, LDL cholesterol
Background: Statins are recognized to be the first line of therapy for lowering cholesterol and have shown to reduce the morbidity and mortality caused by cardiovascular diseases. Atorvastatin and rosuvastatin are potent statins which can efficiently lower the cholesterol and triglyceride levels, we have thus undertaken this study to compare the efficacy of these two statins in non-diabetic patients.
Methods: 150 patients selected for the study, were over 18 years of age with dyslipidemia with no management. Using a randomized computer table, the patients were divided into 2 groups of 75 patients each; group A, who were given atorvastatin 20 mg and group B who were given rosuvastatin 10 mg for 12 weeks. History, and blood tests for fasting blood sugar, hemoglobin A1C, lipid profile such as triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, urea, creatinine, uric acid, creatine kinase, aspartate aminotransferase, and alanine aminotreasferase. Vitamin 25(OH) D, serum insulin and hs-CRP levels were measured after taking the base line details.
Results: The numbers of women were lesser than that of men. There was a considerable reduction in the triglyceride levels, total and LDL levels in both the groups after 12 weeks of use although between the two groups there was not any significant difference. A slight reduction was seen in the hs-CRP levels and elevation in Vit D3 levels though this was not very significant due to the lesser duration of the study.
Conclusions: Both atorvastatin and rosuvastatin are equally powerful statins and very effective in reducing the triglyceride and LDL-cholesterol levels. They are also effective in lowering hs-CRP and elevating vitamin D levels.
Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 1999;340:448-54.
Dyslipidemia. Available at; https://en.wikipedia.org/wiki/Dyslipidemia. Accessed on 12 March 2016.
Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM et al. Heart disease and stroke statistics-2011 update: report from the American Heart Association. Circulation. 2011;123(4):e18-209.
Padmavathi VV, Kambar C, Bano Z, Kurli S, Eswar G, Babu RP. Comparative study of rosuvastatin with atorvastatin in ischemic heart disease patients. IOSR J Dent Med Sci. 2014;13(3):23-9.
Brewer HB Jr. New features of the National cholesterol education program adult treatment panel III lipid-lowering guidelines. Clin Cardiol. 2003;26(4 Suppl 3):III19-24.
Kim YK. Impact of the metabolic syndrome and its components on pulse wave velocity. Korean J Intern Med. 2006;21:109-15.
Boden WE. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management. Curr Opin Cardiol. 2003;18:278-285.
Yood MU, McCarthy BD, Kempf J, Kucera GP, Wells K, Oliveria S et al. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J. 2006;152:777-84.
Leibovitz E, Harats D, Gavish D. Efficacy of atorvastatin in treating high risk patients to reach low density lipoprotein-cholesterol goals: the treat to target (TTT-Israel) study. Isr Med Assoc J. 2002;4:407-10.
Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K: Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J. 1998;19:1434-1503.
Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of scotland coronary prevention study group. N Engl J Med. 1995;333:1301-7.
Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-9.
The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-57.
Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy. Curr Med Res Opinion. 2003;19(6):540-56.
Pella D, Rybar R, Mechirova V. Pleiotropic effects of statins. Acta Cardiologica Sinica. 2005;21(4):190-8.
Watson KE. The Jupiter trial: How will it change clinical practice? Rev Cardiovasc Med. 2009;10(2):91-6.
Ukinc K, Ersoz HO, Erem C, Hacihasanoglu AB, Karti SS. Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. Endocrine. 2009;35:380-8.
Parson HK, Bundy MA, Dublin CB, Boyd AL, Paulson JF, Vinik AI. Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes. Diabetes Metab Syndr Obes. 2010;3:19-26.
McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW et al. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19:689-698.
Clearfield MB, Amerena J, Bassand JP, García HRH, Miller SS, Sosef FFM et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia: prospective study to evaluate the use of low doses of the statins atorvastatin and rosuvastatin (PULSAR). Trials. 2006;7:35.
Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006;97:229-35.
Reiner Z, Catpano AL, De Backer G, Graham I, Taskinen MR, European Association for Cardiovascular Prevention & Rehabilitation, ESC Committee for Practice Guidelines (CPG) 2008,-2010, and 2010,-2012, Committees et al. ESC/EAS Guidelines for the management of dyslipidaemias the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769-818.
Mojiminiyi OA, Abdella NA. Effect of homeostasis model assessment computational method on the definition and associations of insulin resistance. Clin Chem Lab Med. 2010;48:1629-34.
Knoop RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341(7):498-511.
Carswell Cl, Plosker GL, Jarvis B. Rosuvastatin. Drugs. 2002:62(14):2075-85.
Jhala CI, Shah VA Shah UV, Dafda JD. Patterns of cardiac disorders & Epidemiology of Coronary artery disease in Urban population of Ahmedabad. J Indian Med Assoc. 1999;97(6):237-40.
Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004;148(1):H1-9.
Ott C, Raff U, Schneider MP, Titze SI, Schmieder RE. 25-hydroxyvitamin D insufficiency is associated with impaired renal endothelial function and both are improved with rosuvastatin treatment. Clin Res Cardiol. 2013;102:299-304.
Yavuz B, Ertugrul DT, Cil H, Ata N, Akin KO, Yalcin AA et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment a novel pleiotropic effect of statins. Cardiovasc Drugs Ther. 2009;23:295-9.
Pérez-Castrillón JL, Vega G, Abad L, Sanz A, Chaves J, Hernandez G et al. Effects of atorvastatin on vitamin D levels in patients with acute ischemic heart disease. Am J Cardiol. 2007;99:903-5.
Sathyapalan T, Shepherd J, Arnett C, Coady AM, Kilpatrick ES, Atkin SL. Atorvastatin increases 25-hydroxyvitamin D concentrations in patients with polycystic ovary syndrome. Clin Chem. 2010;56:1696-700.